Virtensive
Co-funded by
the European Union

GliCo · by Virtensive

Keeping the result after GLP-1 therapy

GLP-1 medicines help many people lose weight — but many stop within a year, and much of the lost weight tends to return. GliCo is being developed as a non-drug way through that transition: a medical device and a digital companion, designed as one system and built on laboratory evidence.

Get in touch
Body weight Time On GLP-1 therapy After stopping Typical regain What GliCo aims for
Illustrative only — not study data.

The step nobody is supporting

GLP-1 receptor agonists have changed obesity care, but they are rarely taken for ever. Cost, side effects and supply mean many people stop — and when they do, appetite and weight tend to come back.

Today there is no evidence-based, non-drug support for the step off medication. That is the gap GliCo is being built for.

How we are building it

GliCo is at the research and development stage. Three principles shape the work.

1

Evidence first

Design decisions are grounded in laboratory research on human cells before anything reaches a person. We would rather learn early that an idea does not work than find out in a clinical study.

2

Device and software as one system

A non-drug medical device and a digital companion, developed together so that they work as a single, personalised form of support.

3

Built to medical-device standards

Developed under the discipline of the EU Medical Device Regulation from the start, with the aim of clinical investigation and CE marking.

Research funding

Virtensive's research is supported by public funding for research, development and innovation in Estonia.

Co-funded by the European UnionKaasrahastanud Euroopa Liit

Building in-house research capability for GliCo

Programme
Support for intersectoral mobility (Sektoritevahelise mobiilsuse toetamine)
Project number
2021-2027.1.01.26-1982
Project name
Valguse mõju rakkude ainevahetusele ja regulatsioonidele
Period
October 2026 – September 2027

About the project

The project brings an experienced PhD researcher from a university into Virtensive, moving research expertise from academia into a young company and building the company's own laboratory capability.

Aim

To establish within Virtensive the knowledge and methods needed to study how the GliCo approach acts on human cells.

Expected result

A validated in vitro test platform on human cells, providing the scientific basis for the further development of GliCo.

This project is co-funded by the European Union.

About Virtensive

Virtensive is an Estonian health-technology company founded in 2026. It brings together biomedical research, health-data expertise and digital product development to build GliCo, working with research institutions and technology and market partners in Estonia and across Europe.